Log in
NASDAQ:ITRM

Iterum Therapeutics Stock Forecast, Price & News

$0.53
-0.42 (-44.71 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.50
Now: $0.53
$0.56
50-Day Range
$0.58
MA: $0.80
$1.20
52-Week Range
$0.50
Now: $0.53
$7.19
Volume33.81 million shs
Average Volume1.97 million shs
Market Capitalization$11.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.7
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More
Iterum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITRM
CUSIPN/A
Phone353-1903-8920
Employees48

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value($1.88) per share

Profitability

Net Income$-103,130,000.00

Miscellaneous

Market Cap$11.16 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$0.53
-0.42 (-44.71 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

How has Iterum Therapeutics' stock price been impacted by COVID-19?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ITRM shares have decreased by 74.1% and is now trading at $0.5253.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Iterum Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Iterum Therapeutics
.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Iterum Therapeutics
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.80) EPS for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.01.
View Iterum Therapeutics' earnings history
.

What price target have analysts set for ITRM?

6 equities research analysts have issued 1-year target prices for Iterum Therapeutics' stock. Their forecasts range from $1.50 to $9.00. On average, they anticipate Iterum Therapeutics' stock price to reach $4.88 in the next year. This suggests a possible upside of 828.0% from the stock's current price.
View analysts' price targets for Iterum Therapeutics
.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $0.53.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $11.16 million and generates $40,000.00 in revenue each year. The company earns $-103,130,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is www.iterumtx.com.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.